Buy Allergodil® eye drops 0.05%, 6 ml
  • Buy Allergodil® eye drops 0.05%, 6 ml

Allergodil® [Azelastine]

Meda Pharma GmbH & Co. KG
549 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Pharmacological properties:

  • Azelastine is a strong long-acting antiallergic agent. When applied to the mucous membrane, additional anti-inflammatory and membrane-stabilizing effects are manifested. No clinically significant effect on the QT (QTc) interval has been identified.


  • maximum plasma concentrations of azelastine are very low and are detected at or below the limit of measurement.


  • prevention and treatment of seasonal allergic conjunctivitis;
  • treatment of non-seasonal (year-round) allergic conjunctivitis.


The active substance Azelastine hydrochloride.

Azelastine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Allergodil® Meda Pharma GmbH & Co. KG Switzerland eye drops
Allergodil® Meda Pharma GmbH & Co. KG Switzerland spray

No customer reviews for the moment.

Write your review

Write your review

Allergodil® [Azelastine]

Dosage and Administration

Seasonal allergic conjunctivitis:

  • in the absence of other recommendations of the doctor for adults and children from 4 years old, bury 2 times a day (morning and evening) with 1 drop in each eye. If necessary, increase the dose up to 4 times a day, one drop in each eye. The drug is used until the symptoms disappear, but not more than 6 weeks. In the case of the anticipated exposure to the allergen, the drug is used prophylactically.

Off-season (year-round) allergic conjunctivitis:

  • in the absence of other recommendations of the doctor for adults and children from 4 years old, bury 2 times a day (morning and evening) with 1 drop in each eye. If necessary, the dose is increased to 4-x times a day, one drop in each eye.

Duration of use - no more than 6 weeks.

Adverse reactions

The incidence of side effects is defined as follows:
Very often:> 1/10;
Often: <1/10> 1/100;
Infrequently: <1/100> 1/1000;
Rarely: <1/1000> 1/10000;
Very rare: <1/10000.


  • often transient blurred vision, conjunctivitis;
  • rarely - burning sensation in the eye.

Are common:

  • infrequently - a feeling of bitterness in the mouth;
  • very rarely - allergic reactions, headache, asthma, dyspnea, fatigue, flu-like symptoms, pharyngitis, itching, rhinitis.


  • Hypersensitivity to the active substance or other components of the drug;
  • Age up to 4 years;
  • I trimester of pregnancy.

Drug interactions

Not found. In the case of concomitant therapy with other eye drops, you should bury them in the eyes with an interval of at least 15 minutes.

Pregnancy and Lactation

Use in the first trimester of pregnancy is not recommended, and in the second and third trimesters and during lactation it is possible if the possible benefit for the mother exceeds the risk for the fetus / child.

Special instructions

When using eye drops it is not recommended to wear contact lenses.

Impact on the ability to drive. In case of blurring of vision immediately after instillation of the drug, one should refrain from driving and engaging in activities requiring increased attention until it is restored.


Data overdose of the drug is not available.

  • Brand name: Allergodil
  • Active ingredient: Azelastine
  • Dosage form: Eye drops 0.05%.
    6 ml of solution in a vial of translucent high density polyethylene with a dropper of low density polyethylene with a white cap of high density polyethylene.
    1 bottle together with the application instruction is placed in a cardboard pack.
  • Manufacturer: Meda Pharma GmbH & Co. KG
  • Country of Origin: Switzerland

Studies and clinical trials of Azelastine (Click to expand)

  1. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in patients with allergy to Texas mountain cedar pollen
  2. High performance liquid chromatographic determination of azelastine and desmethylazelastine in guinea pig plasma and lung tissue
  3. Chirality of azelastine and flezelastine: Investigation of their enantiomers
  4. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants
  5. Cough Threshold for Capsaicin Increases by Azelastine in Patients with Cough-variant Asthma
  6. Inhibitory effects of a new antiallergic agent, azelastine, on passive cutaneous anaphylaxis and expulsion of Nippostrongylus brasiliensis
  7. Inhibition of calcium ionophore (A23187)-induced histamine release by a novel anti-allergic agent, 4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1h-azepine-4yl)-1(2H)-phthalazinone hydrochloride (azelastine; A5610)
  8. Inhibition of passive cutaneous anaphylaxis (PCA) by azelastine: Dissociation of its antiallergic activities from antihistaminic and antiserotonin properties
  9. Effect of coenzyme ql o and azelastine on protecting radiation pneumonitis in patients with lung cancer
  10. The effect of azelastine on acute radiation dermatitis in mice models
  11. Simultaneous enantioselective separation of azelastine and three of its metabolites for the investigation of the enantiomeric metabolism in rats: I. Liquid chromatography–ionspray tandem mass spectrometry and electrokinetic capillary chromatography
  12. Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography
  13. A study of intranasal distribution of azelastine hydrochloride aqueous nasal spray with different spray techniques
  14. Influence of azelastine and some selected drugs on mucociliary clearance
  15. Suppression of respiratory burst of polymorphonuclear leukocytes by Azelastine hydrochloride (Azeptin)
  16. Azelastine reduces allergen-induced nasal response: a clinical and rhinomanometric assessment
  17. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis
  18. Effects of acrivastine, azelastine, cetirizine and noberastine on rat peritoneal mast cells
  19. Electrophysiological effects of azelastine in isolated guinea pig atrial and ventricular fibers
  20. Azelastine inhibits bronchial hyperreactivity to acetylcholine in guinea pigs
  21. Antagonism of histamine and leukotrienes by azelastine in isolated guinea pig ileum
  22. Mucolytic activity of azelastine in mice and rats
  23. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs
  24. The effect of azelastine on an acute non-specific inflammation in comparison to the effect of dexamethasone

8 other products in the same category: